Harvard Bioscience, Inc. (NASDAQ:HBIO) is a key player in the life science research tools sector. The company provides essential equipment and solutions for scientific research, serving a wide range of clients in the biomedical field. As of March 16, 2026, HBIO will implement a reverse stock split, exchanging every 10 shares for 1 share.
This reverse stock split, approved by the board and stockholders, aims to boost the stock's per-share price. Currently, HBIO's stock price is $0.55, having decreased by 3.68% or $0.021. The split is intended to help the company meet Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange.
The reverse split will legally take effect on March 13, 2026, at 4:30 p.m. Eastern Time. Post-split trading will commence on March 16, 2026. This strategic move is crucial for maintaining HBIO's market presence and investor confidence, as highlighted by the company's recent stock performance.
HBIO's stock has fluctuated between $0.54 and $0.57 today, with a 52-week high of $0.95 and a low of $0.28. The company's market capitalization is approximately $24.6 million, with a trading volume of 313,998 shares. This reverse split is a step towards stabilizing the stock's value and enhancing its market appeal.
